Company will present new platform for the isolation of CTCs from whole blood, and clinical data on mutational profiling of CTCs by next generation sequencing
Westlake Village, CA - October 9, 2012 - Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research and individualized medicine via the molecular characterization of cancer, announced today that it will be co- sponsoring the 3rd annual World CTC USA meeting, at the Hyatt Regency in Boston, Massachusetts on November 12-15, 2012. The World CTC conference brings together the pre-eminent academic and industry researchers focusing on the biotechnology of Circulating Tumor Cells and their impact on drug development and patient treatment.
On November 13th at 2:00 PM EST, Dr. Paul Dempsey, Cynvenio’s Vice President of Bioengineering and Development, will give a presentation entitled “Solving Challenges to Mutation Analysis of Circulating Tumor Cells” in which he will discuss Cynvenio’s new, automated high-throughput platform for the recovery of CTCs from whole blood. Dr. Dempsey will also share new game-changing methods to reliably sequence CTCs without whole genome amplification.
“The meeting is a forum to discuss the latest CTC technology and new paradigms in cancer diagnostics and patient care,” said Andre’ de Fusco, Cynvenio’s CEO. “Cynvenio will be making several product announcements at the event and we look forward to sharing the compelling work we’ve completed in the molecular characterization of CTCs.”
About WORLD CTC Forum:
This event is organized and managed by Hanson Wade (London, England) and detailed information can be found here: http://ctc-summit.com.
About Cynvenio Biosystems, Inc.:
Cynvenio has developed the LiquidBiopsy® platform, a high performance rare cell isolation system that enables the mutational profiling of circulating tumor cells obtained from a simple, minimally invasive blood draw. Cynvenio’s mission in oncology is to develop the tools for the early detection of disease, to enable longitudinal patient monitoring in support of better treatment decisions, and to facilitate the identification of genetically matched therapeutic solutions. Cynvenio is based in Westlake Village, California and is privately held. Find out more about the company here: http://www.cynvenio.com and http://www.liquidbiopsy.com.
LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.
WORLD CTC is a copyright of Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJ.